Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | BTK inhibitors in CLL

Florence Cymbalista • 19 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Zanubrutinib

Florence Cymbalista, MD, of Hôpital Avicenne, Bobigny, France, explores clinical trials evaluating the use of second generation BTK inhibitors such as zanubrutinib and acalabrutinib for chronic lymphocytic leukemia (CLL), and their potential benefits over ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Florence Cymbalista

Towards strategies to optimize outcomes in CLL 2:30
Towards strategies to optimize outcomes in CLL
Florence Cymbalista • 7 Oct 2022
Moving towards time-limited treatment in frontline CLL 2:07
Moving towards time-limited treatment in frontline CLL
Florence Cymbalista • 7 Oct 2022
The importance of TP53 & IGHV testing before treatment initiation in CLL 2:27
The importance of TP53 & IGHV testing before treatment initiation in CLL
Florence Cymbalista • 7 Oct 2022
Challenges in interpreting the results of genomic tests in CLL 1:33
Challenges in interpreting the results of genomic tests in CLL
Florence Cymbalista • 7 Oct 2022

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals